Guggenheim Capital’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$690K Buy
34,680
+8,491
+32% +$181K ﹤0.01% 1114
2026
Q2
$756K Sell
26,189
-11,659
-31% -$314K ﹤0.01% 1125
2026
Q1
$685K Sell
37,848
-6,259
-14% -$119K 0.01% 1112
2025
Q4
$959K Buy
44,107
+8,649
+24% +$248K 0.01% 975
2025
Q3
$1.16M Buy
35,458
+2,871
+9% +$106K 0.01% 870
2025
Q2
$1.16M Sell
32,587
-2,020
-6% -$65.5K 0.01% 832
2025
Q1
$1.17M Sell
34,607
-2,317
-6% -$83.1K 0.01% 822
2024
Q4
$1.2M Buy
36,924
+2,940
+9% +$122K 0.01% 832
2024
Q3
$1.66M Sell
33,984
-2,406
-7% -$128K 0.01% 882
2024
Q2
$1.61M Buy
36,390
+3,030
+9% +$140K 0.01% 892
2024
Q1
$1.87M Buy
33,360
+1,732
+5% +$104K 0.01% 909
2023
Q4
$1.9M Buy
+31,628
New +$2M 0.01% 865

Other funds holding LEGN

Guggenheim Capital's LEGN Position: Q3 2026 in Review

Guggenheim Capital increased its Legend Biotech (LEGN) stake by 32% in Q3 2026, buying an estimated $181K and bringing the position to 34,680 shares worth $690K. The position accounts for ﹤0.01% of the portfolio, ranked #1114.

Guggenheim Capital first reported a position in LEGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.9M in Q4 2023. 197 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • Guggenheim Capital held 34,680 shares of Legend Biotech worth $690K as of Q3 2026.
  • Guggenheim Capital bought 8,491 Legend Biotech shares in Q3 2026, an estimated $181K.
  • Legend Biotech made up ﹤0.01% of Guggenheim Capital's portfolio in Q3 2026, its #1114 holding.
  • Guggenheim Capital first reported a position in Legend Biotech in Q4 2023 and has held it in 12 quarters since.
  • Guggenheim Capital's Legend Biotech position peaked at $1.9M in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Guggenheim Capital's 13F filing for Q3 2026, filed 16 Nov 2026.